Bruce N. Jacobs Sells 7,035 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Bruce N. Jacobs sold 7,035 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the transaction, the chief financial officer now owns 201,886 shares in the company, valued at approximately $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR opened at $31.70 on Thursday. Kymera Therapeutics, Inc. has a 12-month low of $29.07 and a 12-month high of $53.27. The company has a market capitalization of $2.06 billion, a PE ratio of -13.55 and a beta of 2.22. The firm’s 50-day moving average is $38.42 and its two-hundred day moving average is $43.48.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The business had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. HC Wainwright boosted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. BTIG Research assumed coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price objective on the stock. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $38.00 to $57.00 in a report on Monday, December 2nd. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They set a “market perform” rating and a $55.00 price objective on the stock. Finally, Leerink Partners reissued an “outperform” rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $56.69.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently modified their holdings of the company. Blue Trust Inc. raised its position in shares of Kymera Therapeutics by 74.8% in the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after buying an additional 270 shares during the last quarter. State of Wyoming acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $45,000. GF Fund Management CO. LTD. acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV raised its position in shares of Kymera Therapeutics by 53.8% in the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after buying an additional 752 shares during the last quarter. Finally, Quarry LP acquired a new position in shares of Kymera Therapeutics in the third quarter valued at approximately $95,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.